Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer

2021101 citationsJournal Articlebronze Open Access

Authors

ClinicalTrials.gov Identifier: NCT02491983.

Good health and well-being

Published in: JAMA Oncology

Volume 7, Issue 12, pp. 1791-1791

Field-Weighted Citation Impact: 11.47